ArticleEuropean journal of nuclear medicine and molecular imaging2008
The cost effectiveness of 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism.
Article in European journal of nuclear medicine and molecular imaging, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 46 citations in OpenAlex.
- Prediction of 123I-FP-CIT SPECT Results from First Acquired Projections Using Artificial Intelligence.Diagnostics (Basel, Switzerland) · 2025Article
- Diagnostic accuracy ofScientific reports · 2023Article
- Same same but different: dopamine transporter SPECT on scanners with CZT vs. NaI detectors.EJNMMI research · 2023Article
- Impact of age and sex correction on the diagnostic performance of dopamine transporter SPECT.European journal of nuclear medicine and molecular imaging · 2021Article
- Impact of the size of the normal database on the performance of the specific binding ratio in dopamine transporter SPECT.EJNMMI physics · 2020Article
- Automatic classification of dopamine transporter SPECT: deep convolutional neural networks can be trained to be robust with respect to variable image characteristics.European journal of nuclear medicine and molecular imaging · 2019Article
- Nuclear Imaging in the Diagnosis of Clinically Uncertain Parkinsonian Syndromes.Deutsches Arzteblatt international · 2019Review
- Reduction in camera-specific variability in [(123)I]FP-CIT SPECT outcome measures by image reconstruction optimized for multisite settings: impact on age-dependence of the specific binding ratio in the ENC-DAT database of healthy controls.European journal of nuclear medicine and molecular imaging · 2016Article
- Robust, fully automatic delineation of the head contour by stereotactical normalization for attenuation correction according to Chang in dopamine transporter scintigraphy.European radiology · 2015Article
- Patient Survey on Satisfaction and Impact of 123I-Ioflupane Dopamine Transporter Imaging.PloS one · 2015Article
- Clinical routine use of dopamine transporter imaging in 516 consecutive patients.Journal of neurology · 2015Article
- Neuroimaging biomarkers for Parkinson disease: facts and fantasy.Annals of neurology · 2014Review
- CT-based attenuation correction in I-123-ioflupane SPECT.PloS one · 2014Article
- Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes.Journal of neurology, neurosurgery, and psychiatry · 2013Review
- Clinical utility of DaTscan™ (123I-Ioflupane Injection) in the diagnosis of Parkinsonian Syndromes.Degenerative neurological and neuromuscular disease · 2013Review
- FP-CIT SPECT evaluation: time to go beyond visual assessment!European journal of nuclear medicine and molecular imaging · 2012Article
- Visual assessment of dopaminergic degeneration pattern in 123I-FP-CIT SPECT differentiates patients with atypical parkinsonian syndromes and idiopathic Parkinson's disease.Journal of neurology · 2012Article
- Modelling the cost effectiveness of treatments for Parkinson's disease: a methodological review.PharmacoEconomics · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose(123)I-N-omega-fluoropropyl-2-beta-carboxymethoxy-3beta-(4-iodophenyl)nortropane ((123)I-FP-CIT) Single-photon emission computed tomography (SPECT) has been suggested to be a useful diagnostic adjunct in patients with clinically uncertain parkinsonism. We developed a pharmaco-economic (PE) model, evaluating the cost effectiveness of adding (123)I-FP-CIT SPECT to the diagnostic workup. As the model was developed before application of the diagnostic technique in real practice, a predictive validity assessment was performed based on data from a large nationwide patient registry in these patients.
methodsA PE model, using a Markov state transition model, was created, based on literature-derived and clinical expert panel data. Effects were expressed as adequately treated years (ATY). Key input data were compared to the real-life patterns in a nationwide multi-centre clinical setting, based on a complete national registry of 1,701 consecutive patients. The change in initial diagnosis and alteration of management of the patient after SPECT were registered.
resultsIn the PE model, it was calculated that management would change in 48.5% of patients by SPECT and that, over a 5-year period, 1.2 ATYs could be gained at a yearly additional cost of 72 euro. From the studied 1,701 patients, nigrostriatal degeneration was observed in 59.8%, the initial diagnosis was changed in 51.5%, management was altered in 49%, and cost effectiveness was increased to 358 euro per ATY.
conclusionGood correspondence between assumed and observed changes in patient management was found, indicating that (123)I-FP-CIT SPECT is influential in diagnosis and management of patients with uncertain clinical diagnosis of parkinsonism. This can be achieved at a marginal added cost to the health insurance and leads to a significant gain in ATY.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.